1. Home
  2. DRMA vs MTNB Comparison

DRMA vs MTNB Comparison

Compare DRMA & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dermata Therapeutics Inc.

DRMA

Dermata Therapeutics Inc.

HOLD

Current Price

$1.24

Market Cap

5.1M

Sector

Health Care

ML Signal

HOLD

Logo Matinas Biopharma Holdings Inc.

MTNB

Matinas Biopharma Holdings Inc.

HOLD

Current Price

$0.29

Market Cap

5.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DRMA
MTNB
Founded
2014
2013
Country
United States
United States
Employees
9
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1M
5.2M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
DRMA
MTNB
Price
$1.24
$0.29
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
73.9K
4.9M
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.84
EPS
N/A
N/A
Revenue
N/A
$119,750.00
Revenue This Year
N/A
N/A
Revenue Next Year
$650.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.10
$0.23
52 Week High
$7.14
$3.09

Technical Indicators

Market Signals
Indicator
DRMA
MTNB
Relative Strength Index (RSI) 44.20 34.79
Support Level $1.14 N/A
Resistance Level $1.40 $0.70
Average True Range (ATR) 0.09 0.08
MACD -0.01 -0.01
Stochastic Oscillator 15.22 9.36

Price Performance

Historical Comparison
DRMA
MTNB

About DRMA Dermata Therapeutics Inc.

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.

About MTNB Matinas Biopharma Holdings Inc.

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.

Share on Social Networks: